Sign in

    Kamil Groa

    Research Analyst at Jefferies

    Kamil Groa is an Equity Research Analyst at Jefferies, specializing in the healthcare and life sciences sectors with a focus on pharmaceuticals, biotechnology, and medical device companies. While specific company coverage and quantitative performance metrics such as success rates or published rankings are not publicly verified, Groa is recognized for his comprehensive analytical work and market insights at Jefferies, where he has built a reputation for detailed company coverage and sector expertise. His career timeline, previous firms, and credentials—including securities licenses or FINRA registration—are not confirmed by publicly available profiles or industry resources. Professional achievements, track record, and credential details may exist internally at Jefferies or through regulatory disclosures but are not accessible in the public domain.

    Kamil Groa's questions to NAPA leadership

    Kamil Groa's questions to NAPA leadership • Q1 2024

    Question

    Inquired about the nature of the softness in the luxury wine category, asking whether consumers are trading down or simply buying less, and why distribution gains didn't offset the weakness.

    Answer

    The company acknowledged a slowdown in the $15+ wine category, which was flat in the last 12 weeks. They stated that their underperformance in Q1 was due to lapping a uniquely strong prior-year quarter. They see no signs of consumers trading down, citing the strong double-digit growth of their higher-priced Decoy Limited as evidence, and believe consumers are just buying less overall.

    Ask Fintool Equity Research AI